{"protocolSection":{"identificationModule":{"nctId":"NCT06478693","orgStudyIdInfo":{"id":"MTX-GPC3-303"},"organization":{"fullName":"Myeloid Therapeutics","class":"INDUSTRY"},"briefTitle":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","officialTitle":"A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-07-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-05-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-24","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-27","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Myeloid Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 in participants with advanced hepatocellular carcinoma expressing GPC3.","detailedDescription":"MT-303 will be administered intravenously with treatment provided until lack of tolerability or progression. Participants will be enrolled in sequential dose escalation cohorts with determination of dose limiting toxicities with the goal of establishing the (maximum tolerated dose) MTD and (Recommended Phase 2 dose) RP2D."},"conditionsModule":{"conditions":["Hepatocellular Carcinoma"],"keywords":["Liver Cancer","Hepatocellular Carcinoma (HCC)","Glypican-3","Chimeric antigen receptor","CAR-M"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":48,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"MT-303","type":"EXPERIMENTAL","description":"Participants will receive MT-303 through intravenous infusion.","interventionNames":["Drug: MT-303"]}],"interventions":[{"type":"DRUG","name":"MT-303","description":"MT-303","armGroupLabels":["MT-303"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Type, incidence and severity of Adverse Events","description":"Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0","timeFrame":"Up to 2 years from the last dose of Investigational Medicinal Product (IMP)"},{"measure":"Recommended Phase 2 Dose (RP2D)","description":"The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data","timeFrame":"28 days from the last dose of IMP"},{"measure":"Change from baseline in vital signs","description":"Temperature, weight, height, pulse rate and blood pressure will be assessed","timeFrame":"Up to 30 days from the last dose of IMP"},{"measure":"Change in laboratory parameters","description":"Hematology, chemistry, coagulation, virology and urine analysis will be assessed.","timeFrame":"Up to 30 days from the last dose of IMP"},{"measure":"Change from baseline in ECG parameters","timeFrame":"Screening, Day 1 and Day 15"}],"secondaryOutcomes":[{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Plasma concentrations","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Area under Curve","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Time of maximum observed plasma concentration (tmax)","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Plasma Clearance (CL)","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Volume of Distribution (Vd)","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: Mean residence time (MRT)","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess the pharmacokinetics (PK) of MT-303","description":"PK parameter: terminal rate constant (Î»z)","timeFrame":"Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP"},{"measure":"To assess adverse events of special interest (AESI) by measuring infusion reaction","timeFrame":"upto 2 years from the last dose of IMP"},{"measure":"To assess adverse events of special interest (AESI) by measuring cytokine release syndrome (CRS)","timeFrame":"Up to 2 years from the last dose of IMP"},{"measure":"To assess adverse events of special interest (AESI) by measuring immune effector cell-associated neurotoxicity syndrome (ICANS)","timeFrame":"Up to 2 years from the last dose of IMP"},{"measure":"To assess adverse events of special interest (AESI) by measuring hypersensitivity reaction","timeFrame":"Up to 2 years from the last dose of IMP"},{"measure":"To assess adverse events of special interest (AESI) by checking for second primary malignancy","timeFrame":"upto 2 years from the last dose of IMP"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Aged 18 years or older\n* Histological diagnosis of advanced/recurrent or metastatic and/or unresectable HCC. \\[Note: participants with other tumor types expressing GPC3 may be eligible pending a discussion with the Medical Monitor\\]\n* Measurable lesion per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1\n* Child-Pugh score: Class A\n* Adequate organ function\n\nExclusion Criteria\n\n* Known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.\n* Any acute illness including active infection\n* History of liver transplantation or on waiting list\n* Participants with untreated or incompletely treated varices with bleeding or high risk for bleeding\n* Uncontrolled pleural effusion, pericardial effusion, or ascites\n* History of symptomatic congestive heart failure\n* History of chronic or recurrent (within the last year) severe autoimmune or immune mediated disease requiring steroids or other immune-suppressive treatments.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Project Manager","role":"CONTACT","phone":"+61 2 8569 1400","email":"Lucy.FrereScott@novotech-cro.com"},{"name":"Clinical Department","role":"CONTACT","phone":"+1 617 465 1022","email":"303clinical@myeloidtx.com"}],"overallOfficials":[{"name":"Matthew Maurer, MD","affiliation":"Myeloid Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"St Vincent's Hospital","status":"NOT_YET_RECRUITING","city":"Sydney","state":"New South Wales","zip":"2010","country":"Australia","contacts":[{"name":"Hao-Wen Sim, MD","role":"CONTACT"}],"geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Integrated Clinical Oncology Network (ICON) Pty Ltd","status":"NOT_YET_RECRUITING","city":"Woolloongabba","state":"Queensland","zip":"4102","country":"Australia","contacts":[{"name":"Vladimir Andelkovic, MD","role":"CONTACT"}],"geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"The Alfred Hospital","status":"NOT_YET_RECRUITING","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","contacts":[{"name":"Stuart Roberts, MD","role":"CONTACT"}],"geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Linear Clinical Research","status":"RECRUITING","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","contacts":[{"name":"Tim Humphries, MD","role":"CONTACT"}],"geoPoint":{"lat":-32.06987,"lon":115.83757}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000006528","term":"Carcinoma, Hepatocellular"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000000230","term":"Adenocarcinoma"},{"id":"D000008113","term":"Liver Neoplasms"},{"id":"D000004067","term":"Digestive System Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000004066","term":"Digestive System Diseases"},{"id":"D000008107","term":"Liver Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M11113","name":"Liver Neoplasms","relevance":"LOW"},{"id":"M9613","name":"Carcinoma, Hepatocellular","asFound":"Hepatocellular Carcinoma","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M3585","name":"Adenocarcinoma","relevance":"LOW"},{"id":"M7256","name":"Digestive System Neoplasms","relevance":"LOW"},{"id":"M8886","name":"Gastrointestinal Neoplasms","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M11107","name":"Liver Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M11110","name":"Liver Extracts","relevance":"LOW"}],"browseBranches":[{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}